Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CVT begins second regadenoson study

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

CV Therapeutics has initiated a second cardiac perfusion imaging trial of its pharmacologic stress agent regadenoson (CVT-3146), the firm announces April 26. CVT and partner Fujisawa plan to submit an NDA "as quickly as possible." CVT is highlighting a potential safety benefit via regadenoson's selectivity for the A2A-adenosine receptor, responsible for coronary vasodilation. The first Phase III trial started in October 2003...

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog

AstraZeneca’s Farxiga Authorized Generic Aims To Broaden Access As Medicare Price Cut Looms

US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?

It’s Official: FDA Drops Final Rule On LDTs

See All
UsernamePublicRestriction

Register

PS002544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By